A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

NCT07200128 | Completed FDA Drug

• 1 other identifier: B7981115
• Study Type: observational
• Target: 123
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.

Conditions

Severe Alopecia Areata

Keywords

Ritlecitinib; Alopecia Areata

Outcome Measures

Primary Outcomes (3)

• % of patients for whom their clinician was "satisfied" with current control of alopecia areata

  11/15/2023 to 06/10/2024

• % of patients with clinician-assessed mild, moderate, or severe disease

  11/15/2023 to 06/10/2024

• % of patients with clinician assessed progressive, stable, or improving disease

  11/15/2023 to 06/10/2024

Study Arms (1)

Patients with severe Alopecia Areata

Drug: Ritlecitinib

Interventions

Ritlecitinib DRUG

As provided in real world practice

Patients with severe Alopecia Areata

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with severe AA treated with ritlecitinib by dermatologists in the US.

Aged 18 years or older with severe alopecia areata

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Pfizer

New York, New York, 10001, United States

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Alopecia Areata

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: September 30, 2025
• Study Start: February 3, 2025
• Primary Completion: May 30, 2025
• Study Completion: May 30, 2025
• Last Updated: September 30, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)